AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26829494 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithmic physiologic management based on blood pressure and arterial waveform analysis
Number of subjects: 94
Study 26829494 — intervention group
Group type: COMPARATOR
Intervention: Contemporary standards for blood pressure management
Number of subjects: 94
Study 25498055 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard triple therapy with CsA, everolimus twice daily and steroids (group A)
Number of subjects: 139
Study 25498055 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-free immunosuppression (group B)
Number of subjects: 139
Study 25498055 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy once daily (group C)
Number of subjects: 139
Study 22513495 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-session behavioral treatment
Number of subjects: 93
Study 22513495 — intervention group
Group type: COMPARATOR
Intervention: three-session brief family intervention
Number of subjects: 93
Study 20212204 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected eyes
Number of subjects: 454
Study 20212204 — intervention group
Group type: COMPARATOR
Intervention: Fellow eyes
Number of subjects: 454
Study 20212204 — intervention group
Group type: EXPERIMENTAL
Intervention: Foveal threshold
Number of subjects: 454
Study 18511542 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline treatment associated with lid hygiene
Number of subjects: 20
Study 18511542 — intervention group
Group type: COMPARATOR
Intervention: Lid hygiene only
Number of subjects: 20
Study 17697902 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI (80/4.5 microg x 2 inhalations)
Number of subjects: 480
Study 17697902 — intervention group
Group type: COMPARATOR
Intervention: Budesonide pMDI (80 microg x 2 inhalations)
Number of subjects: 480
Study 17697902 — intervention group
Group type: COMPARATOR
Intervention: Formoterol DPI (4.5 microg x 2 inhalations)
Number of subjects: 480
Study 17697902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 15123221 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 400 microg via MDI plus spacer
Number of subjects: 0
Study 15123221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10691818 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (2.4 g/day)
Number of subjects: 16
Study 10691818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9432686 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by concurrent chemoradiotherapy and definitive surgery
Number of subjects: 0
Study 9432686 — intervention group
Group type: COMPARATOR
Intervention: Upfront surgery followed by adjuvant radiation therapy
Number of subjects: 0
Study 9432686 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by definitive concurrent chemoradiation up to 65 Gy radiation dose
Number of subjects: 0
Study 9432686 — intervention group
Group type: COMPARATOR
Intervention: Multimodality program similar to the phase-II protocol with inclusion of definitive surgery
Number of subjects: 0
Study 1302807 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose oral fluconazole (150 mg)
Number of subjects: 0
Study 1302807 — intervention group
Group type: COMPARATOR
Intervention: Three-day local treatment with miconazole pessaries
Number of subjects: 0
Study 3895875 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (300 mg intramuscularly followed by 100 mg intravenously)
Number of subjects: 402
Study 3895875 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 402
Study 3895875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study 31446113 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancrelipase (50,000 units)
Number of subjects: 8
Study 31446113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 28272011 — intervention group
Group type: EXPERIMENTAL
Intervention: Human reticular acellular dermal matrix (HR-ADM)
Number of subjects: 12
Study 28272011 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 12
Study 27703240 — intervention group
Group type: EXPERIMENTAL
Intervention: BK-SE36 vaccine
Number of subjects: 0
Study 27703240 — intervention group
Group type: COMPARATOR
Intervention: Placebo/control group
Number of subjects: 0
Study 24456504 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with temozolomide (Bev-Tem)
Number of subjects: 63
Study 24456504 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with irinotecan (Bev-Iri)
Number of subjects: 63
Study 22096023 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus hypoxic cell cytotoxin, tirapazamine (TPZ)
Number of subjects: 578
Study 22096023 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (control arm)
Number of subjects: 578
Study 19903333 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioural program with a vocational approach
Number of subjects: 89
Study 19903333 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 89
Study 19903333 — intervention group
Group type: COMPARATOR
Intervention: Reference population (disability pensioners with back pain who refused to participate)
Number of subjects: 89
Study 19903333 — intervention group
Group type: COMPARATOR
Intervention: Reference population (disability pensioners with other musculoskeletal disorders)
Number of subjects: 89
Study 17571315 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acids + glucose + fat emulsion (Group B)
Number of subjects: 40
Study 17571315 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose + fat emulsion (Group A)
Number of subjects: 40
Study 17571315 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 40
Study 15478495 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam (Dispersalloy)
Number of subjects: 30
Study 15478495 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectrum TPH
Number of subjects: 30
Study 15478495 — intervention group
Group type: EXPERIMENTAL
Intervention: SureFil
Number of subjects: 30
Study 15478495 — intervention group
Group type: EXPERIMENTAL
Intervention: Esthet‐X
Number of subjects: 30
Study 15478495 — intervention group
Group type: EXPERIMENTAL
Intervention: Esthet‐X + Dyract Flow
Number of subjects: 30
Study 11547052 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine ureteral stenting after ureteroscopy (group 1)
Number of subjects: 295
Study 11547052 — intervention group
Group type: COMPARATOR
Intervention: No ureteral stenting after ureteroscopy (group 2)
Number of subjects: 295
Study 11547052 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine ureteral stenting (group 1)
Number of subjects: 295
Study 11547052 — intervention group
Group type: COMPARATOR
Intervention: No ureteral stenting (group 2)
Number of subjects: 295
Study 9493256 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance data analysis
Number of subjects: 0
Study 9493256 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measures of weight loss, drug plasma level, and pill count data
Number of subjects: 0
Study 7931890 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose, short-duration ribavirin aerosol therapy (6 gm/100 ml water for 2 hours three times a day)
Number of subjects: 32
Study 7931890 — intervention group
Group type: COMPARATOR
Intervention: Standard ribavirin aerosol therapy (6 gm/300 ml water for 18 hours daily)
Number of subjects: 32
Study 2438880 — intervention group
Group type: EXPERIMENTAL
Intervention: Dithranol (0.1, 0.5, 1, 2%)
Number of subjects: 30
Study 2438880 — intervention group
Group type: EXPERIMENTAL
Intervention: Dithranol in Lassar's paste
Number of subjects: 30
Study 2438880 — intervention group
Group type: COMPARATOR
Intervention: Butantrone (0.66, 1.3, 2.7, 3.9%)
Number of subjects: 30
Study 29453464 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietitian-led lifestyle modification programme (D-LMP)
Number of subjects: 52
Study 29453464 — intervention group
Group type: COMPARATOR
Intervention: Conventional paediatrician-led consultation (P-CON)
Number of subjects: 52
Study 26183686 — intervention group
Group type: EXPERIMENTAL
Intervention: Piragliatin 200 mg BID
Number of subjects: 59
Study 26183686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 24632089 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow theta oscillations (3 Hz)
Number of subjects: 0
Study 24632089 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast theta oscillations (7 Hz)
Number of subjects: 0
Study 23739279 — intervention group
Group type: EXPERIMENTAL
Intervention: solution (N-acetylcysteine and simethicone)
Number of subjects: 75
Study 23739279 — intervention group
Group type: COMPARATOR
Intervention: water control (100 ml sterile water)
Number of subjects: 75
Study 23739279 — intervention group
Group type: COMPARATOR
Intervention: standard control (clear fluids only)
Number of subjects: 75
Study 20562781 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dose regimen of amitriptyline (n=30)
Number of subjects: 60
Study 20562781 — intervention group
Group type: COMPARATOR
Intervention: Empiric dose regimen of amitriptyline (n=30)
Number of subjects: 60
Study 18687758 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker panel score derived from beta2M, cystatin C, hsCRP, and glucose
Number of subjects: 540
Study 18687758 — intervention group
Group type: COMPARATOR
Intervention: Conventional risk factors (age, smoking status, diabetes status)
Number of subjects: 540
Study 16914413 — intervention group
Group type: EXPERIMENTAL
Intervention: PMEA-coated CPB circuits (n = 19)
Number of subjects: 39
Study 16914413 — intervention group
Group type: COMPARATOR
Intervention: Non-coated CPB circuits (n = 20)
Number of subjects: 39
Study 11874427 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (15 mg/day)
Number of subjects: 134
Study 11874427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 10201469 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (100 mg by i.v. infusion immediately before endoscopy)
Number of subjects: 529
Study 10201469 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride administered in the same fashion)
Number of subjects: 529
Study 7773086 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol, 10 mg once a day
Number of subjects: 14
Study 7773086 — intervention group
Group type: COMPARATOR
Intervention: Propranolol, 80 mg twice a day
Number of subjects: 14
Study 7773086 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol, 100 mg twice a day
Number of subjects: 14
Study 7773086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2090533 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg once a day)
Number of subjects: 0
Study 2090533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 376355 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 200 mg daily for 100 days
Number of subjects: 40
Study 376355 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study 30651007 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined auriculotherapy (LAT + MAT)
Number of subjects: 62
Study 30651007 — intervention group
Group type: COMPARATOR
Intervention: Placebo auriculotherapy (placebo LAT + placebo MAT)
Number of subjects: 62
Study 30651007 — intervention group
Group type: COMPARATOR
Intervention: Magneto-auriculotherapy (MAT) alone
Number of subjects: 62
Study 29945169 — intervention group
Group type: EXPERIMENTAL
Intervention: P27A antigen (10 or 50 μg) with Alhydrogel or GLA-SE (2.5 or 5 μg)
Number of subjects: 56
Study 29945169 — intervention group
Group type: EXPERIMENTAL
Intervention: P27A antigen with Alhydrogel
Number of subjects: 56
Study 29945169 — intervention group
Group type: EXPERIMENTAL
Intervention: P27A antigen with GLA-SE
Number of subjects: 56
Study 29945169 — intervention group
Group type: COMPARATOR
Intervention: Control rabies vaccine (Verorab)
Number of subjects: 56
Study 29945169 — intervention group
Group type: EXPERIMENTAL
Intervention: P27A antigen
Number of subjects: 56
Study 28176150 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily monetary incentives
Number of subjects: 0
Study 28176150 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed monetary incentives
Number of subjects: 0
Study 28176150 — intervention group
Group type: COMPARATOR
Intervention: No incentives
Number of subjects: 0
Study 28176150 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 28176150 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily incentive condition
Number of subjects: 0
Study 25882659 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PEMF therapy (60 minutes; frequency: 12 Hz; intensity: 12 Gauss)
Number of subjects: 13
Study 25882659 — intervention group
Group type: COMPARATOR
Intervention: Nonactive PEMF (control group)
Number of subjects: 13
Study 23727255 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin (MV) supplementation
Number of subjects: 138
Study 23727255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 21855759 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of betamethasone acetate 5.7 mg/mL (Group 1)
Number of subjects: 400
Study 21855759 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 0.1% eyedrops (Group 2)
Number of subjects: 400
Study 19074930 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective CPAP therapy
Number of subjects: 31
Study 19074930 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 31
Study 19074930 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 31
Study 17318417 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHu‐EPO) at doses of 20, 40, 60, 90, 120, and 160 kIU
Number of subjects: 48
Study 17318417 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHu‐EPO)
Number of subjects: 48
Study 15260961 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dextroamphetamine (AMPH, 0.25 mg/kg)
Number of subjects: 8
Study 15260961 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 8
Study 11699803 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous porcine secretin
Number of subjects: 56
Study 11699803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 9070554 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0
Study 8436714 — intervention group
Group type: EXPERIMENTAL
Intervention: Back massage with normal conversation
Number of subjects: 21
Study 8436714 — intervention group
Group type: COMPARATOR
Intervention: Conversation only
Number of subjects: 21
Study 8436714 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 21
Study 3094058 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (15 micrograms/kg)
Number of subjects: 0
Study 3094058 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.65 mg/kg)
Number of subjects: 0
Study 3094058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30499799 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 300
Study 30499799 — intervention group
Group type: COMPARATOR
Intervention: Standard gauze dressing
Number of subjects: 300
Study 30499799 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT) among patients receiving a stoma
Number of subjects: 300
Study 30499799 — intervention group
Group type: COMPARATOR
Intervention: Standard gauze dressing among patients receiving a stoma
Number of subjects: 300
Study 28830411 — intervention group
Group type: EXPERIMENTAL
Intervention: Moringa oleifera (M.O.) Lam. leaf powder supplementation (daily for 6 months)
Number of subjects: 60
Study 28830411 — intervention group
Group type: COMPARATOR
Intervention: Nutritional counseling (over 6 months)
Number of subjects: 60
Study 26268774 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosexual counselling before and after surgery (arm A)
Number of subjects: 30
Study 26268774 — intervention group
Group type: COMPARATOR
Intervention: PPI without psychosexual counselling (arm B)
Number of subjects: 30
Study 26268774 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosexual counselling (arm A)
Number of subjects: 30
Study 26268774 — intervention group
Group type: COMPARATOR
Intervention: PPI alone (arm B)
Number of subjects: 30
Study 23632235 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) supplementation, 3 g CLA/d for 6 weeks
Number of subjects: 34
Study 23632235 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sunflower oil) for 6 weeks
Number of subjects: 34
Study 21590648 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (titrated to 45 mg/day)
Number of subjects: 201
Study 21590648 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (titrated to 15 mg/day)
Number of subjects: 201
Study 19225433 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafilcon A (high oxygen permeability)
Number of subjects: 20
Study 19225433 — intervention group
Group type: COMPARATOR
Intervention: Etafilcon A (low oxygen permeability)
Number of subjects: 20
Study 19225433 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbscan measurements
Number of subjects: 20
Study 19225433 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measurements
Number of subjects: 20
Study 17053155 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (1296 mg EPA + 864 mg DHA/day) for 8 weeks
Number of subjects: 20
Study 17053155 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil supplementation (3510 mg alpha-linolenic acid + 900 mg linoleic acid/day) for 8 weeks
Number of subjects: 20
Study 15051770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural bleomycin (83 patients)
Number of subjects: 160
Study 15051770 — intervention group
Group type: COMPARATOR
Intervention: Intrapleural interferon alfa-2b (IFN) (77 patients)
Number of subjects: 160
Study 11094870 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy and its combinations with other therapeutic physical factors
Number of subjects: 328
Study 9278195 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral (5 mg kg(‐1) dose)
Number of subjects: 10
Study 9278195 — intervention group
Group type: COMPARATOR
Intervention: CsA capsules (5 mg kg(‐1) dose)
Number of subjects: 10
Study 1329172 — intervention group
Group type: EXPERIMENTAL
Intervention: Group sequential method for determining study duration in clinical trials
Number of subjects: 0
Study 1329172 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 3978249 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (30 mg daily)
Number of subjects: 98
Study 3978249 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus nandrolone decanoate (100 mg i.m. once a week for four weeks, then every other week)
Number of subjects: 98
Study 3978249 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 98
Study 3978249 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus nandrolone decanoate
Number of subjects: 98
Study 3625143 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum only
Number of subjects: 99
Study 3625143 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum with extensive personal instruction
Number of subjects: 99
Study 3625143 — intervention group
Group type: COMPARATOR
Intervention: Control group (no desire to stop smoking)
Number of subjects: 99
Study 30950795 — intervention group
Group type: EXPERIMENTAL
Intervention: The Adventures of DoReMiFa (digital game-based and school-based intervention)
Number of subjects: 459
Study 30950795 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 459
Study 29275597 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% pre-ASIR-V with 60% post-ASIR-V image reconstruction
Number of subjects: 160
Study 29275597 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroups B2-B10, C2-C3, D1-D2
Number of subjects: 160
Study 29275597 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroups B4-B10, C2-C3, D1-D2
Number of subjects: 160
Study 29275597 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroups B3-B8, C2-C3, D1-D2
Number of subjects: 160
Study 29275597 — intervention group
Group type: COMPARATOR
Intervention: Control group (40% ASIR)
Number of subjects: 160
Study 26283753 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality simulation training (40 minutes using a haptic transvaginal simulator)
Number of subjects: 34
Study 26283753 — intervention group
Group type: COMPARATOR
Intervention: Conventional teaching (40 minutes including a conference with slides and videos)
Number of subjects: 34
Study 23374998 — intervention group
Group type: EXPERIMENTAL
Intervention: Floor Reaction Orthoses (FROs) optimised for ankle stiffness
Number of subjects: 32
Study 23374998 — intervention group
Group type: COMPARATOR
Intervention: Shoes alone
Number of subjects: 32
Study 21474675 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDM) 5 g/m² as a 24-hour infusion at weeks 4, 7, 10, and 13
Number of subjects: 436
Study 21474675 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDM)
Number of subjects: 436
Study 21474675 — intervention group
Group type: COMPARATOR
Intervention: No high-dose methotrexate (no HDM)
Number of subjects: 436
Study 18372169 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0
Study 18372169 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study 16492230 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan NS 20 mg
Number of subjects: 738
Study 16492230 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan NS 5 mg
Number of subjects: 738
Study 16492230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 738
Study 14556671 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa treatment
Number of subjects: 0
Study 14556671 — intervention group
Group type: COMPARATOR
Intervention: Delayed epoetin alfa treatment
Number of subjects: 0